Back to News
Market Impact: 0.2
Raymond James Initiates Coverage of Kymera Therapeutics with Outperform Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Raymond James initiated coverage of Kymera Therapeutics with an Outperform recommendation on October 9, 2026. The stock had closed at $109.30 on October 8; the article excerpt is truncated and provides no subsequent share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
KYMR0.55
More News
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- William Blair downgrades Alignment Healthcare stock rating on cost pressures
- Here are Friday's biggest analyst calls: Nvidia, SpaceX, Tesla, Boeing, Apple, American Express & more
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- Cramer: Investors selling Apple on latest iPhone 18 report are 'stupid as plywood'